ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 727

International Classification of Functioning, Disability, and Health (ICF) Core Sets for Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) and Idiopathic Pulmonary Fibrosis (IPF) – a Necessary Map to Health Care Provision in the Era of ICD-11

Reuben Escorpizo1,2, Kevin J. Keen3, Kim Fligelstone4, Matthew R. Lammi5, Daphne LeSage6, Anne-Marie Russell7, Surinder Birring8, Catherine Sarver9, Janos Varga10, Oliver Distler11 and Lesley Ann Saketkoo12, 1ICF Research Branch in cooperation with the WHO Collaborating Centre for the Family of International Classifications in Germany (DIMDI), Nottwil, Switzerland, 2Department of Physical Therapy, 2Louisiana State University Health Sciences Center, New Orleans, LA, 3University of Northern British Columbia, Health Research Institute, Prince George, BC, Canada, 4Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, 5Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, 6Center for CCH at State of Louisiana, New Orleans, LA, 7National Heart Lung Institute, Royal Brompton Hospital,, London, United Kingdom, 8King's College Hospital NHS Foundation Trust, London, United Kingdom, 9Johns Hopkins, Baltimore, MD, 10National Koranyi Institute for TB and Pulmonology, Budapest, Hungary, 11Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 12Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Health equity, interstitial lung disease and outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics: Systemic Sclerosis Measures and Outcomes

Session Type: Abstract Submissions (ACR)

Background/Purpose: A recent consensus project (Saketkoo et al, Thorax 2014) recommended a minimum core set of outcome measures for use in future clinical trials of CTD-ILD and IPF.  The World Health Organization (WHO) introduced the International Classification of Functioning, Disability, and Health (ICF) as a scientific method of disability data collection and a universal framework of >1200 categories to describe disability associated with health conditions in terms of the bio-psycho-social model with consideration of environmental and personal factors.  For accurate representation of disease, ease of healthcare provision and fair allocation of resources, it is essential that ICF Core Sets be established for rare and complex diseases.

Methods: Per updated ICF linkage rules, each instrument from the published CTD-ILD and IPF core sets were deconstructed to meaningful concepts and independently linked by 2 health professionals experienced in ICF linkage (RE, LAS). Inter-linker agreement on independent linkages was analyzed (KK).  Discordant linkages were resolved between linkers.  A 3rd linker (OD) arbitrated if irreconcilable linkages occurred.

Results: Eighty-two ICF categories were identified under the 4 ICF domains for 6 patient questionnaires and 3 traditional objective measures.  The proportion of agreement ranged from 0.79 (95% CI: 0.62, 0.91) to 0.93 (0.76, 0.99) (Table 1) on the 5 different survey instruments (Table 2) with the overall proportion of inter-linker agreement 0.86 (0.82, 0.89). Any discordant linkages were reconciled between the initial 2 linkers. A previously linked version of the SF-36 had already existed; All-Cause Mortality and Patient Global of Disease Activity were indefinable in ICF terms.  20 new Personal Factors were generated to capture important disease-specific qualities not elsewhere described in ICF, e.g. ‘pf_embarrassed by cough’ or ‘pf_panic/afraid when can’t get breath’.

 

Conclusion: This is the first effort to map CTD-ILD and IPF outcome measures to the ICF. A composite of these ICF linkages will be available to clinicians and researchers with validation studies to follow. ICF Core Sets are intended to be stream-lined disease-specific languages that support global, regional and personal health-related parity across cultures, age and socioeconomic status. ICF Core Sets enable fair assessment that may be utilized in policy making and service provision and funding. Familiarity with ICF Core Sets in CTD-ILD and IPF will enable clinicians to experience a smoother transition to ICD-11 which is under development and will meld diagnostic coding with the ICF.


Disclosure:

R. Escorpizo,
None;

K. J. Keen,
None;

K. Fligelstone,
None;

M. R. Lammi,
None;

D. LeSage,
None;

A. M. Russell,
None;

S. Birring,
None;

C. Sarver,
None;

J. Varga,
None;

O. Distler,

Actelion, Pfizer, Ergonex, BMS, Bayer, United BioSource Corporation, Roche/Genentech, medac, Biovitrium, Boehringer Ingelheim Pharma, Novartis, 4D Science, Active Biotec, Sinoxa, Sanofi-Aventis, Serodapharm, GSK, Epipharm, ,

5,

Actelion, Pfizer, Ergonex, Sanofi-Aventis,

2;

L. A. Saketkoo,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/international-classification-of-functioning-disability-and-health-icf-core-sets-for-connective-tissue-disease-interstitial-lung-disease-ctd-ild-and-idiopathic-pulmonary-fibrosis-ipf/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology